<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745806</url>
  </required_header>
  <id_info>
    <org_study_id>RD007</org_study_id>
    <nct_id>NCT04745806</nct_id>
  </id_info>
  <brief_title>Post Marketing Trial for Evaluating the Effectiveness of ActiGraft in Treating Lower Extremity Hard To Heal Wounds</brief_title>
  <official_title>A Prospective, Single Arm, Post Marketing Study for Evaluating the Effectiveness of ActiGraft in Treating Lower Extremity Hard to Heal Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RedDress Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RedDress Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, single arm, post- marketing study. The subjects enrolled to the&#xD;
      study will receive weekly applications of ActiGraft until complete healing or until&#xD;
      investigator's decision that patient can no longer benefit from the study treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Reduction in Wound Size Over 12 Weeks</measure>
    <time_frame>4, 8, and 12 weeks</time_frame>
    <description>The change in wound area (decrease or increase) with respect to the area at baseline, expressed as a percentage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a Complete Wound Closure at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Skin re-epithelialization without drainage or dressing requirements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a Complete re-epithelialization at 18 and 24 Weeks</measure>
    <time_frame>18 and 24 weeks</time_frame>
    <description>Skin re-epithelialization without drainage or dressing requirements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Reduction in Wound Size Over 18 and 24 Weeks.</measure>
    <time_frame>18 and 24 weeks</time_frame>
    <description>The change in wound area (decrease or increase) with respect to the area at baseline, expressed as a percentage for wound treated beyond 12 weeks, per the investigator's decision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in wound pain by 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pain assessment would be done by using the Numeric Rating Scale (NRS). Subject chooses a number on a 1 to 10 scale that best describes his ulcer pain, while 0 represents &quot;No Pain&quot; and 10- &quot; Worst Pain Imaginable &quot;test, a scale between .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Wounds</condition>
  <arm_group>
    <arm_group_label>ActiGraft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole blood clot (WBC) gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ActiGraft</intervention_name>
    <description>Whole blood clot (WBC) gel</description>
    <arm_group_label>ActiGraft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is ≥18 years of age&#xD;
&#xD;
          2. Patient with a chronic lower extremity ulcer (i.e DFU, VLU, …)&#xD;
&#xD;
          3. Ulcer duration &gt;30 days.&#xD;
&#xD;
          4. Ulcer size decreased in less than 30% in the 14 days prior to enrollment, while&#xD;
             treated with standard of care (or advanced treatment)&#xD;
&#xD;
          5. Subject must be willing to comply with the protocol including having blood drawn to&#xD;
             create the ActiGraft&#xD;
&#xD;
          6. Subject can read and understand the Informed Consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of active underlying osteomyelitis.&#xD;
&#xD;
          2. Known malignancy in the reference wound bed or margins of the wound&#xD;
&#xD;
          3. Cannot withdraw blood in the required amount technically.&#xD;
&#xD;
          4. Subject is receiving (i.e., within the past 30 days) systemic steroids (more than 10mg&#xD;
             per day)&#xD;
&#xD;
          5. Subject has been treated with wound dressings that include growth factors, engineered&#xD;
             tissues or skin substitutes (within the past 30 days).&#xD;
&#xD;
          6. Subject has been treated with hyperbaric oxygen, wound VAC or Ozone gas(O3) within the&#xD;
             past 5 days or is scheduled to receive during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Sirota</last_name>
    <role>Study Director</role>
    <affiliation>RedDress Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sahar Boostenay</last_name>
    <phone>+972544621243</phone>
    <email>sboostenay@reddressmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Sirota</last_name>
    <phone>+972545800765</phone>
    <email>sharon@reddress.co.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rotem Swartzman</last_name>
      <phone>+972-52-5935391</phone>
      <email>rotem_sw@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Aziz Shoufani, Dr. Med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamar Halperin, Dr. Med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic</keyword>
  <keyword>Ulcer</keyword>
  <keyword>Lower extremity</keyword>
  <keyword>DFU</keyword>
  <keyword>VLU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The results will be part of several scientific publications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Upon publication.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

